pharmaphorum December 21, 2023
Indivior has secured a $111 million supply contract from the US federal government for its intranasal therapy for treating opioid overdose, in a further boost to the UK company’s fortunes.
The award from the Biomedical Advanced Research and Development Authority (BARDA) will be used in part to create a stockpile of 200,000 doses of Opvee, the first nalmefene-based nasal spray to be approved for use in the US, which Indivior acquired as part of its $145 million acquisition of Opiant Pharma in February.
The FDA approved Opvee as an emergency treatment for individuals aged 12 or over who are suspected of having taken an overdose of natural or synthetic opioids. Some of the BARDA funding will be used to assist...
Today's Sponsors
Today's Sponsor